NOVN N Stock Overview
Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Novartis AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 2,236.00 |
| 52 Week High | CHF 2,236.00 |
| 52 Week Low | CHF 2,236.00 |
| Beta | 0.51 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 27.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| NOVN N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -2.7% | 0.7% |
| 1Y | n/a | -25.1% | -10.1% |
Return vs Industry: Insufficient data to determine how NOVN N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how NOVN N performed against the MX Market.
Price Volatility
| NOVN N volatility | |
|---|---|
| NOVN N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.0% |
| 10% least volatile stocks in MX Market | 2.7% |
Stable Share Price: NOVN N's share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine NOVN N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 76,057 | Vas Narasimhan | www.novartis.com |
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.
Novartis AG Fundamentals Summary
| NOVN N fundamental statistics | |
|---|---|
| Market cap | Mex$4.05t |
| Earnings (TTM) | Mex$237.12b |
| Revenue (TTM) | Mex$1.01t |
17.1x
P/E Ratio4.0x
P/S RatioIs NOVN N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVN N income statement (TTM) | |
|---|---|
| Revenue | US$49.94b |
| Cost of Revenue | US$12.07b |
| Gross Profit | US$37.87b |
| Other Expenses | US$26.11b |
| Earnings | US$11.76b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
| Earnings per share (EPS) | 5.88 |
| Gross Margin | 75.83% |
| Net Profit Margin | 23.55% |
| Debt/Equity Ratio | 69.8% |
How did NOVN N perform over the long term?
See historical performance and comparison